Search research articles
Contact Us
Filters
Showing results (1-10 of 42) with videos related to
Page
of 5
Sort By:
Breast Cancer Research and Treatment
|
September 28, 2013
Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer
Ariadna Tibau, Marguerite Ennis, Pamela J Goodwin
European Journal of Internal Medicine
|
August 24, 2019
Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals
Daniel Shepshelovich, Dafna Yahav, Ariadna Tibau, et al.
Acta Haematologica
|
June 6, 2019
Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies
Anat Gafter-Gvili, Ariadna Tibau, Pia Raanani, et al.
Journal of Cancer Policy
|
June 5, 2025
Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992-2024)
Kristina Jenei, Georg Hahn, Aaron S Kesselheim, et al.
BMJ (Clinical Research Ed.)
|
August 20, 2024
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study
Ariadna Tibau, Thomas J Hwang, Jerry Avorn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2026
Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis
Guanqiao Li, Yiwen Pu, Congzhou Chen, et al.
Cancer
|
July 30, 2019
Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines
Ramy R Saleh, Habeeb Majeed, Ariadna Tibau, et al.
Cancer Medicine
|
July 29, 2021
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
Brooke E Wilson, Alexandra Desnoyers, Michelle B Nadler, et al.
JAMA Oncology
|
April 4, 2024
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies
Ariadna Tibau, Thomas J Hwang, Consolacion Molto, et al.
Mayo Clinic Proceedings
|
January 7, 2019
Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials
Daniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 42) with videos related to
Sort By:
Page
of 5
Breast Cancer Research and Treatment
|
September 28, 2013
Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer
Ariadna Tibau, Marguerite Ennis, Pamela J Goodwin
European Journal of Internal Medicine
|
August 24, 2019
Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals
Daniel Shepshelovich, Dafna Yahav, Ariadna Tibau, et al.
Acta Haematologica
|
June 6, 2019
Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies
Anat Gafter-Gvili, Ariadna Tibau, Pia Raanani, et al.
Journal of Cancer Policy
|
June 5, 2025
Trends in time to withdrawal and full approval of accelerated approval cancer drug indications (1992-2024)
Kristina Jenei, Georg Hahn, Aaron S Kesselheim, et al.
BMJ (Clinical Research Ed.)
|
August 20, 2024
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study
Ariadna Tibau, Thomas J Hwang, Jerry Avorn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2026
Risk of bias and clinical benefit of phase III trials supporting FDA-approved anticancer medicines, 2018-2025: A cross-sectional analysis
Guanqiao Li, Yiwen Pu, Congzhou Chen, et al.
Cancer
|
July 30, 2019
Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines
Ramy R Saleh, Habeeb Majeed, Ariadna Tibau, et al.
Cancer Medicine
|
July 29, 2021
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
Brooke E Wilson, Alexandra Desnoyers, Michelle B Nadler, et al.
JAMA Oncology
|
April 4, 2024
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies
Ariadna Tibau, Thomas J Hwang, Consolacion Molto, et al.
Mayo Clinic Proceedings
|
January 7, 2019
Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials
Daniel Shepshelovich, Ariadna Tibau, Hadar Goldvaser, et al.
Page
of 5